Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO E-Learning: Multidisciplinary Treatment for Glioblastoma

New E-learning module by Matthias Preusser is now available. View the presentation now and take the CME test!

Learning objectives

  • To provide an update on key diagnostic, clinical, molecular, prognostic and predictive characteristics in patients with newly diagnosed and recurrent glioblastoma
  • To describe best practices and current treatment recommendations
  • To provide an update on recent clinical trials and ongoing research seeking to improve treatment outcomes

After two years E-Learning modules are no longer considered current. There is therefore no CME test associated with this E-Learning module.

Title Duration Content CME Points CME Test
Multidisciplinary Treatment for Glioblastoma 20 min. 25 slides - -

Glioblastoma is the most common primary brain tumour in adult patients. It is a cancer type characterised with a high morbidity and mortality, with a median overall survival of 14 to 17 months. This E-learning module is part of ESMO effort to provide an update on standard treatment recommendations and raise interest among a new generation of oncologists towards a type of disease in which research is a key factor towards improved outcomes.

Most patients develop de novo tumours with a short clinical history of days to a few months (primary glioblastoma) and less than 10% of tumours develop from lower grade gliomas (secondary glioblastomas), typically with a clinical history of years. The clinical presentation is highly variable and it depends on tumour localisation and size.

Standard first-line therapy consists of maximal safe resection and combined radiochemotherapy with temozolomide. Currently there is no accepted treatment standard for recurrent glioblastoma. Supportive treatment with anti-oedema and anticonvulsive therapy is of particular importance in most patients. Ongoing trials evaluate novel strategies for newly diagnosed glioblastoma and patients with recurrent glioblastoma.  

In this E-learning module, the author covers in a very educational manner: 

  • epidemiology of glioblastoma,
  • relative frequencies of gliomas,
  • risk factors,
  • clinical presentation,
  • neuroimaging features,
  • histopathology features,
  • molecular pathology,
  • prognostic factors,
  • standard treatment strategies in newly diagnosed and patients with recurrent glioblastoma,
  • current therapy schedule and key recommendations based on randomised phase III trials,
  • treatment specificities in elderly patients,
  • standards in anti-oedema and anticonvulsive therapies, as well as a summary on currently ongoing research strategies

This E-Learning module was published in 2015 and expired in 2017.

Last update: 05 Aug 2015

The author has reported to have received grants from Roche, GSK, Boehringer-Ingelheim, MSD and honoraria from GSK, Roche and BMS

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings